Attorney Docket No. 20078.0001USWO

The specification of which

## HAMRE, SCHUMANN, MUELLER & LARSON, P.C.

## **United States Patent Application**

## COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: METHOD OF AMPLIFYING NUCLEIC ACID AND METHOD OF DETECTING MUTATED NUCLEIC ACID USING THE SAME

applicable) (in the c	20 June 2006 as application serial ase of a PCT-filed application) de	escribed and claimed in in	d was amended on (if nternational no. PCT/JP2004/01934e wed and for which I solicit a United
I hereby state that I claims, as amended	have reviewed and understand the by any amendment referred to ab	e contents of the above-id	lentified specification, including the
for patent or invento	or's certificate listed below and ha	ve also identified below a	19/365 of any foreign application(s any foreign application for patent or asis of which priority is claimed:
a. no such application such application	cations have been filed.		
	FOREIGN APPLICATION(S), IF ANY	, CLAIMING PRIORITY UNDER	35 USC § 119
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
Japan	2003-431003	25 December 2003	
Japan	2004-313910	28 October 2004	
	ALL FOREIGN APPLICATION(S), IF ANY,	FILED BEFORE THE PRIORITY	APPLICATION(S)
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
in the prior United S	below and, insofar as the subject tates application in the manner pro-	matter of each of the clais covided by the first parage	United States and PCT internations of this application is not disclose raph of Title 35, United States Code ability as defined in Title 37, Code of the code ability as defined in Title 37, Code of the code ability as defined in Title 37, Code of the code ability as defined in Title 37, Code of the code of

ıl d Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

any United States provisional		
any Ontice States provisional		
DATE OF FILING (Day, Month, Year)		

I acknowledge the duty to disclose information that is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (reprinted below):

## § 1.56 Duty to disclose information material to patentability.

- (a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
  - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
- (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim;

or

- (2) It refutes, or is inconsistent with, a position the applicant takes in:
  - (i) Opposing an argument of unpatentability relied on by the Office, or
  - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
  - (1) Each inventor named in the application:
  - (2) Each attorney or agent who prepares or prosecutes the application; and

- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.
- (e) In any continuation-in-part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby appoint the attorney(s) and/or patent agent(s) associated with the following customer number to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith.

52835 PATENT TRADEMARK OFFICE

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/ organization who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct, Hamre, Schumann, Mueller & Larson P.C. to the contrary.

I understand that the execution of this document, and the grant of a power of attorney, does not in itself establish an attorney-client relationship between the undersigned and the law firm Hamre, Schumann, Mueller & Larson P.C., or any of its attorneys.

Please direct all correspondence in this case to customer number 52835.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

				Andreas de la constitución de la		
	Full Name	Family Name	First Given Name		Second Given Name	
2	Of Inventor	MITANI	Yasumasa			
0	Residence	City	State or Foreign Country		Country of Citizenship	
	& Citizenship	Aki-Takata-shi	Hiroshima		Japan	
1	Mailing	Address	City		State & Zip Code/Country	
	Address	c/o Wakunaga Pharmaceutical Co., Ltd., 1624, Shimo- Koutachi, Kouda-cho	Aki-Takata-shi		Hiroshima 739-1105/Japan	
Sign	ature of Inventor 2	101: Yacumasa Mitani		Date:	uly. 27.2006	
	Full Name	Family Name	First Given Name		Second Given Name	
2	Of Inventor	OKA	Takanori			
0	Residence	City	State or Foreign Country		Country of Citizenship	
	& Citizenship	Aki-Takata-shi	Hiroshima		Japan	
2	Mailing	Address	City		State & Zip Code/Country	
	Address	c/o Wakunaga Pharmaceutical Co., Ltd., 1624, Shimo- Koutachi, Kouda-cho	Aki-Takata-shi		Hiroshima 739-1105/Japan	
Slgn	ature of Inventor 2	102: Tal 5 /		Date:	wrast. 4 200h	
	Full Name	Family Name	First Given Name	7	Becond Given Name	
2	Of Inventor	HAYASHIZAKI	Yoshihide			
0	Residence	City	State or Foreign Country		Country of Citizenship	
	& Citizenship	Tsukuba-shi	Iharaki		Japan	
3	Mailing	Address	City		State & Zip Code/Country	
	Address	22-8, Inarimae	Tsukuba-shi	D 4	Ibaraki 305-0061/Japan	
Signature of Inventor 203:				Date:	427 2006	
	Full Name	Family Name	First Given Name		Second Given Name	
2	Of Inventor	HAYASHI	Toshizo		0.00	
0	Residence	Clty	State or Foreign Country		Country of Citizenship	
	& Citizenship	Yokohama-shi	Kanagawa		Јарал	
4	Mailing	Address	City		State & Zip Code/Country	
	Address	c/o Kabushiki Kaisha Dnaform, 75-1, Ono-cho, Tsurumi-ku	Yokohama-shi		Kanagawa 230-0046/Japan	
Signature of Inventor 204:  Date: Sugart 1, 2006						
<u>.                                    </u>	- 1.29 - 1pc - 1 - 1/2	t yuj	**	Jagar		
		. /		•		